Patents Examined by Lorraine Spector
  • Molting hormone receptor and method for screening ligand to the receptor
    Patent number: 7422863
    Abstract: The present invention provides a completely novel molting hormone receptor, which is used for efficiently screening a substance that can be applied to a disinfestant or the like. An insect molting hormone receptor comprising the following polypeptide (a) and polypeptide (b) or (c): (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1; (b) a polypeptide having the amino acid sequence shown in SEQ ID NO: 2; and (c) a polypeptide having the amino acid sequence shown in SEQ ID NO: 3.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: September 9, 2008
    Assignees: Kumiai Chemical Industry Co., Ltd., Hiromichi Nagasawa
    Inventors: Hiromichi Nagasawa, Norihiko Izawa, Yutaka Kurihara, Shinji Nagata, Takafumi Maruyama
  • CASH (Caspase Homologue) with death effector domain, modulators of the function of FAS
    Patent number: 7419804
    Abstract: Proteins capable of modulating or mediating the function of MORT-1 are disclosed. Also disclosed are DNA sequences encoding these proteins, the recombinant production of these proteins as well as their use.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: September 2, 2008
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Yura Goltsev, Andrei Kovalenko, Eugene Varfolomeev, Vadim Brodianski
  • Receptor that causes cell death and recombinant production thereof
    Patent number: 7416877
    Abstract: Isolated apoptosis inducing receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: August 26, 2008
    Assignee: Immunex Corporation
    Inventors: Mariapia A. Degli-Esposti Rankin, Raymond G. Goodwin
  • Estrogen receptor genes and utilization thereof
    Patent number: 7410778
    Abstract: A gene coding for any of the following estrogen receptors (a) to (c): (a) an estrogen receptor comprising the amino acid sequence represented by amino acid numbers 153 to 602 in the amino acid sequence of SEQ ID NO: 1, (b) an estrogen receptor comprising the amino acid sequence of SEQ ID NO: 1, and (c) an estrogen receptor comprising an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence represented by amino acid numbers 153 to 602 in the amino acid sequence of SEQ ID NO: 1; and the like.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: August 12, 2008
    Assignee: Sumitomo Chemical Company Limited
    Inventor: Koichi Saito
  • Monoclonal blocking antibody to human RANKL
    Patent number: 7411050
    Abstract: Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: August 12, 2008
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Method of identifying activity modulators of a polycystin-2L1 taste receptor polypeptide
    Patent number: 7407769
    Abstract: Taste receptor polycystin-2L1 is provided. Methods and systems for screening for tastants and receptor modulators are provided. Knock out and transgenic animals, methods of detecting polymorphisms, and methods of correcting taste defects are also provided.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: August 5, 2008
    Assignee: The Regents of the University of California
    Inventors: Charles Zuker, Angela L. Huang
  • Therapeutic compositions of oncomodulin
    Patent number: 7407937
    Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: August 5, 2008
    Assignee: Children's Medical Center Corporation
    Inventors: Larry I. Benowitz, Yuqin Yin
  • Method of screening antiplatelet agents
    Patent number: 7405051
    Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: July 29, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Jun Takasaki, Mitsuyuki Matsumoto, Masazumi Kamohara, Tetsu Saito, Takahide Ohishi, Takatoshi Soga
  • Chemically targeted positional identification of post-translationally phosphorylated peptides
    Patent number: 7402407
    Abstract: Methods are provided for determining the position of a post-translationally modified (PTM) amino acid residue such as a phosphorylated amino acid residue or an O-glycosylated amino acid residue in a peptide. Also provided are methods for determining the identity of a PTM amino acid residue in a peptide. In addition, kits for practicing such methods are provided.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: July 22, 2008
    Assignee: California Institute of Technology
    Inventor: Gary M. Hathaway
  • Methods of using G-CSF analog compositions
    Patent number: 7402304
    Abstract: The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: July 22, 2008
    Assignee: Massachusetts Institute of Technology
    Inventors: Casim A. Sarkar, Douglas A. Lauffenburger, Bruce Tidor
  • Chemokine PANEC-2 polypeptides and compositions and methods related thereto
    Patent number: 7396652
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: July 8, 2008
    Assignee: INCYTE Corporation
    Inventors: Roger T. Coleman, Olga Bandman, Craig G. Wilde
  • Method of producing an antibody to G-protein parathyroid hormone receptor HLTDG74
    Patent number: 7393650
    Abstract: Human G-protein parathyroid hormone (PTH) receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the PTH receptor receptor polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the PTH receptor receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host. Disclosed embodiments of the invention also include antibodies that bind Human G-Protein parathyroid hormone (PTH) receptor polypeptides and methods for making and using such antibodies.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: July 1, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Daniel R. Soppet, Yi Li, Craig A. Rosen, Steven M. Ruben
  • Immunostimulatory combinations
    Patent number: 7387271
    Abstract: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: June 17, 2008
    Assignees: 3M Innovative Properties Company, Trustees of Dartmouth College
    Inventors: Randolph J. Noelle, Cory L. Ahonen, Ross M. Kedl
  • Growth factor homolog zvegf3 polynucleotides
    Patent number: 7387885
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: June 17, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker, Debra G. Gilbertson, James W. West
  • Connective tissue growth factor
    Patent number: 7384634
    Abstract: The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF and polynucleotides regulating CTGF expression. The invention also provides agents that modulate CTGF and therapeutic methods for using the agents. Also provided are diagnostic methods for using CTGF and assays for identifying agents which affect the expression of CTGF polynucleotide.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: June 10, 2008
    Assignee: University of South Florida
    Inventors: Gary R. Grotendorst, Douglass M. Bradham, Jr.
  • Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
    Patent number: 7381805
    Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: June 3, 2008
    Assignee: Maxygen Holdings, Ltd.
    Inventors: Carsten Germansen, Bobby Soni, Grethe Rasmussen
  • Canine IL-13 receptor alpha-1 subunit nucleic acid molecules
    Patent number: 7378275
    Abstract: The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13R?) proteins, particularly canine interleuken receptor alpha 1 (IL-13R?1) and canine interleuken receptor alpha 2 (IL-13R?2) proteins. Also included are canine IgG and IL-13R? proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: May 27, 2008
    Assignee: Heska Corporation
    Inventors: Catherine A. McCall, Liang Tang
  • Growth factor homolog zvegf4
    Patent number: 7375182
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: May 20, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard
  • PRO9783 polypeptides
    Patent number: 7371817
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Compositions and methods of using angiopoietin-like 4 protein antibody
    Patent number: 7371384
    Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang